Yahoo Web Search

Search results

    • Image courtesy of dropcarepharm.com

      dropcarepharm.com

      • Today, the U.S. Food and Drug Administration approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity.
      www.fda.gov › news-events › press-announcements
  1. FDA approves Wegovy (semaglutide) injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition.

  2. People also ask

  3. The FDA approved a new use for a drug to reduce the risk of cardiovascular disease, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight.

  4. Jul 14, 2022 · When an early Wegovy trial showed the drug’s power, Kurtzhals says it felt “too good to be true”. Then a late-stage trial confirmed the stunning weight loss, and the team celebrated.

  5. Jun 10, 2021 · The FDA on Friday approved a new weight-loss drug, Wegovy, for people who are either obese or overweight and have at least one weight-related medical problem.

    • Chief Medical Correspondent
    • 2 min
  6. Aug 25, 2023 · A study found that a 2.4-milligram weekly dose of semaglutide, sold as Wegovy for weight loss, led to an improvement of 17 points on a 100-point scale that’s used to assess symptoms of a...

    • Meg Tirrell
  7. Jun 4, 2021 · The Food and Drug Administration approved Wegovy, a higher-dose version of Novo Nordisk's diabetes drug semaglutide, for long-term weight management. In company-funded studies, participants...

  8. Aug 17, 2023 · And results from a clinical trial reported last week indicate that Wegovy can do more than help people lose weight — it also can protect against cardiac complications, like heart attacks and...

  1. People also search for